Skip to main content

Table 2 Patient characteristics at TKI discontinuation

From: Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

Parameter

Data

Age, years

 Median

64

 Range

24–84

Duration of TKI therapy before stop, months

 Median

100

 Range

25–202

Time to DMR, months

 Median

56*

 Range

13–207

DMR duration, months

 Median

44

 Range

(0–100)

Initial treatment

 IFN-α

3 (12%)

 Imatinib

20 (80%)

 Nilotinib

2 (8%)

Treatment at discontinuation

 Imatinib

20 (80%)

 Nilotinib

1 (4%)

 Dasatinib

4 (16%)

Reason for TKI discontinuation

 SDMR

19 (76%)

  SDMR

18 (95%)

  SDMR/adverse event

1 (5%)

 UDMR

6 (24%)

  UDMR/clinician and patient decision

2 (33%)

  UDMR/adverse event

3 (50%)

  UDMR/pulmonary tuberculosis

1 (17%)

Response at TKI discontinuation

 MR5.0

12 (48%)´

 MR4.5

12 (48%)

 MR4.0

1 (4%)

 MMR

0 (0%)

  1. *One patient did not achieved DMR and was not included in this analysis; TKI, tyrosine kinase inhibitor; DMR, deep molecular response; SDMR, sustained deep molecular response; UDMR, unsustained deep molecular response;MR5.0, ≥5-log reduction from IRIS baseline; MR4.5, ≥4.5-log reduction from IRIS baseline; MR4.0, ≥4.0-log reduction from IRIS baseline; MMR, major molecular response